Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,207,609 papers from all fields of science
Search
Sign In
Create Free Account
dodecyl 2-(N,N-dimethylamino)propionate
Known as:
DDAIP
, DMAL 12s cpd
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Alanine
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,NDimethylaminopropionate (DDAIP)
S. Meier-Davis
,
Salma Debar
,
Richard M. Martin
,
M. Hachicha
,
B. Damaj
2012
Corpus ID: 71739486
Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N, NDimethylaminopropionate (DDAIP) Penetration…
Expand
2011
2011
Abstract 1297: DDAIP improves the pharmacokinetic profile of PrevOnco® in different species: Comparison of DDAIP, CMC and PEG-300/400 formulations in mice, beagle dogs and cynomolgus monkeys
K. Dines
,
F. Incardona
,
M. Hachicha
,
Richard M. Martin
,
B. Damaj
2011
Corpus ID: 71900182
Our study in the accompanying abstract demonstrates that a low dose of PrevOnco® in combination with doxorubicin was efficacious…
Expand
1995
1995
Calcein efflux from stratum corneum lipid liposomes by penetration enhancers azone, dodecanol, and DDAIP
T. Suhonen
,
Mervi Raisanen
,
A. Urtti
,
Petteri Paronene
1995
Corpus ID: 88898748
1993
1993
Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino)propionate on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone
S. Büyüktimkin
,
N. Büyüktimkin
,
J. Rytting
Pharmaceutical Research
1993
Corpus ID: 2273708
The biodegradable transdermal penetration enhancer, dodecyl 2-(N,N-dimethylamino)propionate (II; DDAIP), was prepared by reacting…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE